Abvacc, Inc.
Rockville, MD
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4 Research Ct #310, Rockville, MD 20850, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $21,963 |
| FY2024 | $0 |
| FY2023 | $69,231 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| To develop a potent therapeutic marburgvirus monoclonal antibody. | National Institute of Allergy and Infectious Diseases (NIH) | $3,467,335 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Texas Medical Branch At Galveston | R01AI160226 | $713,552 |
Similar vendors
About the company
Abvacc, Inc. is a for-profit biotechnology company located in Rockville, Maryland, specializing in the development of advanced medical countermeasures and immunotherapeutic solutions targeting critical infectious diseases. Registered in SAM.gov since December 2022, the company focuses on developing innovative therapeutic and prophylactic approaches for challenging viral pathogens, with a particular emphasis on emerging infectious diseases and biodefense applications. The company operates as a corporate entity and has demonstrated significant capabilities in monoclonal antibody research, vaccine development, and advanced immunological interventions.
Regarding federal contract awards, Abvacc, Inc. has secured a notable cost-plus-fixed-fee definitive contract from the National Institute of Allergy and Infectious Diseases (NIAID) valued at $16,927,478.76. This contract, awarded in May 2021, specifically targets the development of a potent therapeutic monoclonal antibody for Marburg virus. The contract, which runs through April 2025, was not set aside for any specific business category and will be executed in Potomac, Maryland. The award leverages NIAID's Omnibus Broad Agency Announcement and represents the company's capabilities in developing advanced medical countermeasures against high-risk pathogens.
In terms of federal grant awards, Abvacc, Inc. has received multiple project grants from NIAID focusing on critical infectious disease research. These grants include a $638,953 award to develop an immunotherapeutic antibody cocktail for Staphylococcus aureus bacteremia, a project running from August 2025 to July 2030. Additionally, the company has secured grants for developing Marburg virus subunit vaccines, including a project to create a vaccine adjuvanted with a novel TLR7/TLR8 agonist and another grant for developing a monoclonal antibody cocktail for Marburg virus disease treatment. The company has also received a grant focused on prophylactic immunotherapy for Marburg virus outbreak control and another addressing immunotherapy for MRSA osteomyelitis. These grants demonstrate Abvacc's expertise in developing advanced immunological interventions for complex infectious diseases, with a strong focus on creating novel therapeutic and preventive strategies.
Quick answers
Is Abvacc, Inc. registered in SAM.gov?
Yes. Abvacc, Inc.'s SAM.gov registration is active through September 15, 2027.
What is Abvacc, Inc.'s CAGE code?
Abvacc, Inc.'s CAGE code is 9FDC1, and its Unique Entity ID (UEI) is K5MSGRFGVVZ9.
How much has Abvacc, Inc. received in federal contracts?
Federal contracts obligated $21,963 to Abvacc, Inc. in fiscal year 2025 and $91,194 in fiscal years 2023 through 2027.
What is Abvacc, Inc.'s most recent federal award?
Abvacc, Inc.'s most recent federal grant award is A multimodal approach for immunotherapy of staphylococcus aureus bacteremia - staphylococcus aureus (S. Aureus; SA)… (R01AI193221), from National Institute of Allergy and Infectious Diseases (NIH), on August 22, 2025.
On GovTribe
See Abvacc, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors